|
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., . . . Group, C. S. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 384(5), 403-416. https://doi.org/10.1056/NEJMoa2035389 Bayati, A., Kumar, R., Francis, V., & McPherson, P. S. (2021). SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem, 296, 100306. https://doi.org/10.1016/j.jbc.2021.100306 Bestle, D., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Klenk, H. D., Garten, W., Steinmetzer, T., & Bottcher-Friebertshauser, E. (2020). TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance, 3(9). https://doi.org/10.26508/lsa.202000786 Bettini, E., & Locci, M. (2021). SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines (Basel), 9(2). https://doi.org/10.3390/vaccines9020147 Cdc Covid- Response Team. (2020a). Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020. MMWR Morb Mortal Wkly Rep, 69(15), 477-481. https://doi.org/10.15585/mmwr.mm6915e6 Cdc Covid- Response Team. (2020b). Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep, 69(12), 343-346. https://doi.org/10.15585/mmwr.mm6912e2 Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., ... & Das, R. (2022). A Bivalent Omicron-containing Booster Vaccine Against Covid-19. medRxiv. https://doi.org/10.1101/2022.06.24.22276703 Chan, J. F., Yuan, S., Kok, K. H., To, K. K., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C., Poon, R. W., Tsoi, H. W., Lo, S. K., Chan, K. H., Poon, V. K., Chan, W. M., Ip, J. D., Cai, J. P., Cheng, V. C., Chen, H., . . . Yuen, K. Y. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 395(10223), 514-523. https://doi.org/10.1016/S0140-6736(20)30154-9 Chen, B. M., Cheng, T. L., & Roffler, S. R. (2021). Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano, 15(9), 14022-14048. https://doi.org/10.1021/acsnano.1c05922 Chen, P. H. (2021). Taiwan’s Efforts to Recreate Remdesivir. Biotechnology Law Report, 40(3), 174-183. https://doi.org/10.1089/blr.2021.29227.phc Chen, W. H., Strych, U., Hotez, P. J., & Bottazzi, M. E. (2020). The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep, 7(2), 61-64. https://doi.org/10.1007/s40475-020-00201-6 Chu, L., McPhee, R., Huang, W., Bennett, H., Pajon, R., Nestorova, B., Leav, B., & m, R. N. A. S. G. (2021). A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 39(20), 2791-2799. https://doi.org/10.1016/j.vaccine.2021.02.007 Connors, M., Graham, B. S., Lane, H. C., & Fauci, A. S. (2021). SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Ann Intern Med, 174(5), 687-690. https://doi.org/10.7326/M21-0111 Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schafer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., . . . Graham, B. S. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 586(7830), 567-571. https://doi.org/10.1038/s41586-020-2622-0 Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O'Connell, S., Bock, K. W., Minai, M., Nagata, B. M., Andersen, H., Martinez, D. R., Noe, A. T., Douek, N., Donaldson, M. M., Nji, N. N., Alvarado, G. S., Edwards, D. K., . . . Graham, B. S. (2020). Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med, 383(16), 1544-1555. https://doi.org/10.1056/NEJMoa2024671 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 5(4), 536-544. https://doi.org/10.1038/s41564-020-0695-z Creech, C. B., Anderson, E., Berthaud, V., Yildirim, I., Atz, A. M., Melendez Baez, I., ... & Schnyder Ghamloush, S. (2022). Evaluation of mRNA-1273 COVID-19 vaccine in children 6 to 11 years of age. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2203315 Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R., & Suthar, M. S. (2021). Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA, 325(18), 1896-1898. https://doi.org/10.1001/jama.2021.4388 Graham, B. S., Mascola, J. R., & Fauci, A. S. (2018). Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases. JAMA, 319(14), 1431-1432. https://doi.org/10.1001/jama.2018.0345 Granstrand, O. (1999). The economics and management of intellectual property : towards intellectual capitalism. E. Elgar Pub. Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan, K. S., Wang, D. Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 7(1), 11. https://doi.org/10.1186/s40779-020-00240-0 Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jamal, A., Jeanes, C., Kalra, P. A., Kyriakidou, C., McAuley, D. F., . . . nCo, V. S. G. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med, 385(13), 1172-1183. https://doi.org/10.1056/NEJMoa2107659 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., & Pohlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271-280 e278. https://doi.org/10.1016/j.cell.2020.02.052 Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., & Pohlmann, S. (2005). Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A, 102(22), 7988-7993. https://doi.org/10.1073/pnas.0409465102 Hsieh, S. M., Liu, M. C., Chen, Y. H., Lee, W. S., Hwang, S. J., Cheng, S. H., Ko, W. C., Hwang, K. P., Wang, N. C., Lee, Y. L., Lin, Y. L., Shih, S. R., Huang, C. G., Liao, C. C., Liang, J. J., Chang, C. S., Chen, C., Lien, C. E., Tai, I. C., & Lin, T. Y. (2021). Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med, 9(12), 1396-1406. https://doi.org/10.1016/S2213-2600(21)00402-1 Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., 2nd, . . . m, R. N. A. S. G. (2020). An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med, 383(20), 1920-1931. https://doi.org/10.1056/NEJMoa2022483 Jara, A., Undurraga, E. A., Gonzalez, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., Sans, C., Leighton, P., Suarez, P., Garcia-Escorza, H., & Araos, R. (2021). Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med, 385(10), 875-884. https://doi.org/10.1056/NEJMoa2107715 Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., Choe, H., & Farzan, M. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426(6965), 450-454. https://doi.org/10.1038/nature02145 Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Rohss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., Brito, L. A., Salter, H., Ciaramella, G., & Lore, K. (2017). Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Mol Ther, 25(12), 2635-2647. https://doi.org/10.1016/j.ymthe.2017.08.006 Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., . . . Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395(10224), 565-574. https://doi.org/10.1016/S0140-6736(20)30251-8 Malik, J. A., Mulla, A. H., Farooqi, T., Pottoo, F. H., Anwar, S., & Rengasamy, K. R. R. (2021). Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother, 137, 111254. https://doi.org/10.1016/j.biopha.2021.111254 Malone, B., Urakova, N., Snijder, E. J., & Campbell, E. A. (2022). Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat Rev Mol Cell Biol, 23(1), 21-39. https://doi.org/10.1038/s41580-021-00432-z Martinez, C. (2011). Patent families: When do different definitions really matter? Scientometrics, 86(1), 39-63. Masters, P. S. (2006). The molecular biology of coronaviruses. Adv Virus Res, 66, 193-292. https://doi.org/10.1016/S0065-3527(06)66005-3 Moderna, Inc. (2013). ASTRAZENECA AND MODERNA THERAPEUTICS ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP PIONEERING MESSENGER RNA THERAPEUTICS™ IN CARDIOMETABOLIC DISEASES AND CANCER. https://investors.modernatx.com/news/default.aspx Moderna, Inc. (2019). 2018 Annual Report. https://s29.q4cdn.com/435878511/files/doc_financials/2018/ar/Chasen-Richter-Moderna-Annual-Report-2018.pdf Moderna, Inc. (2020a). News. https://investors.modernatx.com/news/default.aspx Moderna, Inc. (2020b). Pipeline. https://web.archive.org/web/20200204103332/https://www.modernatx.com/pipeline Moderna, Inc. (2020c). 2019 Annual Report. https://s29.q4cdn.com/435878511/files/doc_financials/2019/ar/Chasen-Richter-Moderna-Annual-Report-2019.pdf Moderna, Inc. (2021). News. https://investors.modernatx.com/news/default.aspx Moderna, Inc. (2022a). Moderna Seminar Series. Chapter 5: Lipid Nanoparticles. https://mrna-access.modernatx.com/resources/topicWebinarSeries Moderna, Inc. (2022b). MODERNA SUES PFIZER AND BIONTECH FOR INFRINGING PATENTS CENTRAL TO MODERNA'S INNOVATIVE MRNA TECHNOLOGY PLATFORM. https://investors.modernatx.com/news/news-details/2022/Moderna-Sues-Pfizer-and-BioNTech-for-Infringing-Patents-Central-to-Modernas-Innovative-mRNA-Technology-Platform/default.aspx Moderna, Inc. (2022c). Patents. https://www.modernatx.com/patents Moderna, Inc. (2022d). STATEMENT BY MODERNA ON INTELLECTUAL PROPERTY MATTERS DURING THE COVID-19 PANDEMIC. https://investors.modernatx.com/Statements--Perspectives/Statements--Perspectives-Details/2020/Statement-by-Moderna-on-Intellectual-Property-Matters-during-the-COVID-19-Pandemic/default.aspx Muthumani, K., Falzarano, D., Reuschel, E. L., Tingey, C., Flingai, S., Villarreal, D. O., Wise, M., Patel, A., Izmirly, A., Aljuaid, A., Seliga, A. M., Soule, G., Morrow, M., Kraynyak, K. A., Khan, A. S., Scott, D. P., Feldmann, F., LaCasse, R., Meade-White, K., . . . Weiner, D. B. (2015). A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med, 7(301), 301ra132. https://doi.org/10.1126/scitranslmed.aac7462 National Institutes of Health. (2020). NIH clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins National Institutes of Health. (2022). COVID-19 Vaccines. https://covid19.nih.gov/covid-19-vaccines Ou, T., Mou, H., Zhang, L., Ojha, A., Choe, H., & Farzan, M. (2021). Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. PLoS Pathog, 17(1), e1009212. https://doi.org/10.1371/journal.ppat.1009212 Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov, 17(4), 261-279. https://doi.org/10.1038/nrd.2017.243 Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release, 217, 345-351. https://doi.org/10.1016/j.jconrel.2015.08.007 Parham, P. (2015). The immune system (Fourth edition. ed.). W. W. Norton & Company. Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Perez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Jr., Hammitt, L. L., . . . Group, C. C. T. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577 Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Ther Deliv, 7(5), 319-334. https://doi.org/10.4155/tde-2016-0006 Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., Almarsson, O., Stanton, M. G., & Benenato, K. E. (2018). A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Mol Ther, 26(6), 1509-1519. https://doi.org/10.1016/j.ymthe.2018.03.010 Sadoff, J., Gray, G., Vandebosch, A., Cardenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Van Dromme, I., Spiessens, B., Vingerhoets, J., Custers, J., Scheper, G., Robb, M. L., Treanor, J., Ryser, M. F., Barouch, D. H., Swann, E., Marovich, M. A., . . . Group, E. S. (2022). Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med, 386(9), 847-860. https://doi.org/10.1056/NEJMoa2117608 Salvatori, G., Luberto, L., Maffei, M., Aurisicchio, L., Roscilli, G., Palombo, F., & Marra, E. (2020). SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J Transl Med, 18(1), 222. https://doi.org/10.1186/s12967-020-02392-y Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020). Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A, 117(21), 11727-11734. https://doi.org/10.1073/pnas.2003138117 Tanriover, M. D., Doganay, H. L., Akova, M., Guner, H. R., Azap, A., Akhan, S., Kose, S., Erdinc, F. S., Akalin, E. H., Tabak, O. F., Pullukcu, H., Batum, O., Simsek Yavuz, S., Turhan, O., Yildirmak, M. T., Koksal, I., Tasova, Y., Korten, V., Yilmaz, G., . . . CoronaVac Study, G. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 398(10296), 213-222. https://doi.org/10.1016/S0140-6736(21)01429-X Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Clutterbuck, E. A., Collins, A. M., Cutland, C. L., Darton, T. C., Dheda, K., Dold, C., . . . Oxford, C. V. T. G. (2021). Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, 397(10277), 881-891. https://doi.org/10.1016/S0140-6736(21)00432-3 Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 183(6), 1735. https://doi.org/10.1016/j.cell.2020.11.032 Wang, C., Zheng, X., Gai, W., Zhao, Y., Wang, H., Wang, H., Feng, N., Chi, H., Qiu, B., Li, N., Wang, T., Gao, Y., Yang, S., & Xia, X. (2017). MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget, 8(8), 12686-12694. https://doi.org/10.18632/oncotarget.8475 Wang, F., Kream, R. M., & Stefano, G. B. (2020). An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. Med Sci Monit, 26, e924700. https://doi.org/10.12659/MSM.924700 Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K. Y., Wang, Q., Zhou, H., Yan, J., & Qi, J. (2020). Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell, 181(4), 894-904 e899. https://doi.org/10.1016/j.cell.2020.03.045 Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., Oliveira, T. Y., Yang, Z., Abernathy, M. E., Huey-Tubman, K. E., Hurley, A., Turroja, M., West, K. A., Gordon, K., Millard, K. G., . . . Nussenzweig, M. C. (2021). mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 592(7855), 616-622. https://doi.org/10.1038/s41586-021-03324-6 Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., Daley, G. Q., Brack, A. S., Collins, J. J., Cowan, C., Schlaeger, T. M., & Rossi, D. J. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618-630. https://doi.org/10.1016/j.stem.2010.08.012 World Health Organization. (2020a). Novel Coronavirus (2019-nCoV) Situation Report – 22. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf World Health Organization. (2020b). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) World Health Organization. (2022, Jul 3). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ Wrobel, A. G., Benton, D. J., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020). SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat Struct Mol Biol, 27(8), 763-767. https://doi.org/10.1038/s41594-020-0468-7 Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265-269. https://doi.org/10.1038/s41586-020-2008-3 Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., & Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 63(3), 457-460. https://doi.org/10.1007/s11427-020-1637-5 Yang, Z. Y., Kong, W. P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., & Nabel, G. J. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 428(6982), 561-564. https://doi.org/10.1038/nature02463 Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Spater, D., Xu, H., Tabebordbar, M., Gorbatov, R., Sena, B., Nahrendorf, M., Briscoe, D. M., Li, R. A., Wagers, A. J., Rossi, D. J., Pu, W. T., & Chien, K. R. (2013). Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol, 31(10), 898-907. https://doi.org/10.1038/nbt.2682 Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., . . . Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270-273. https://doi.org/10.1038/s41586-020-2012-7 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., Tan, W., China Novel Coronavirus, I., & Research, T. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 382(8), 727-733. https://doi.org/10.1056/NEJMoa2001017 Huang, Kathy. (2022, Jun 9). 莫德納推新型追加劑!二價疫苗更能抗Omicron。基因線上。https://geneonline.news/moderna-omicron-booster/ 孚創雲端(2022a)。全文資訊。https://helpcenter.inquartik.com/zh-hk/%E5%85%A8%E6%96%87%E8%B3%87%E8%A8%8A 孚創雲端(2022b)。專利文獻數據範圍。https://app.patentcloud.com/data-status.html?__hstc=92158149.bb12c559382a96cc47aa8195cee8afd2.1657575509348.1658091894174.1658138250601.6&__hssc=92158149.4.1658281984375&__hsfp=1808647293&_gl=1*ourpmn*_ga*NTgyNDI5NjcuMTY1NzU3NTUwOQ..*_ga_GTLMQEG9VF*MTY1ODI5MzEzNS40NS4xLjE2NTgyOTMzMjkuMA..&_ga=2.109879686.284098141.1658042089-58242967.1657575509 張玄竺、廖月娟、鍾榕芳、黃瑜安(譯)(2022)。疫苗商戰:新冠危機下AZ、BNT、輝瑞、莫德納、嬌生、Novavax的生死競賽。臺北市:天下文化。 (Gregory Zuckerman, 2021) 陳秉訓(2014)。台灣醫院的台灣專利申請行為之分析。臺北科技大學學報,46(1),47-61。 陳達仁、黃慕萱(2018)。專利資訊檢索、分析與策略。華泰文化。 郭妍希(2021年05月21日)。莫德納考慮赴亞洲製造疫苗!CEO:已開始接洽日企。MoneyDJ新聞。https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=6fca31b6-1b74-452f-ac10-03d475c53fb5 楊智傑(2014)。專利法。新學林。 葉士緯、洪菁蔓、周光宇(2016)。我國導入臨時申請案制度之可行性探討。智慧財產權月刊,205,40-64。 經濟部智慧財產局(2022)。專利審查基準彙編(111年7月1日施行版)。 劉國讚(2021)。國際專利分析與布局。元照。 謝銘洋(2004)。智慧財產權之基礎理論。翰蘆圖書。
|